SLG
SYRE icon

Stanley-Laman Group’s Spyre Therapeutics SYRE Stock Holding History

Stanley-Laman Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,401
Closed -$371K – 236
2018
Q2 		$371K Buy
1,401
+923
+193% +$227K 0.08% 232
2018
Q1 		$118K Buy
+478
New +$86.4K 0.03% 259

Other funds holding SYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stanley-Laman Group's SYRE Position: Q3 2018 in Review

Stanley-Laman Group sold out of Spyre Therapeutics (SYRE) in Q3 2018, closing a stake of 1,401 shares — an estimated $371K sold.

Stanley-Laman Group first reported a position in SYRE in Q1 2018 and held it in 2 quarters. The position peaked at $371K in Q2 2018. 59 funds tracked by Wall St. Rank hold SYRE as of Q3 2018.

  • Stanley-Laman Group reported no remaining Spyre Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 1,401 Spyre Therapeutics shares in Q3 2018, an estimated $371K.
  • Stanley-Laman Group first reported a position in Spyre Therapeutics in Q1 2018 and held it in 2 quarters.
  • Stanley-Laman Group's Spyre Therapeutics position peaked at $371K in Q2 2018.
  • 59 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2018.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.